Abbreviated R-CHOP in Completely Excised Stage I or II DLBCL

Phase 2 Unknown 32 enrolled Asan Medical Center

NaSingle-groupOpen-labelTreatment

Summary

This study aims; to assess the efficacy of shortened systemic chemotherapy in patients with completely excised CD20 positive Diffuse Large B-cell Lymphoma (DLBCL) with Ann Arbor Stage I or II.

Timeline

Start: 2010-08
Primary completion: 2016-08
Completion: 2017-01

Publications

Kang S, Cho H, Sohn BS, Oh SY, Lee WS, Lee SM, Yang DH, Huh J, Yoon DH, Suh C. Long-term follow-up of abbreviated R-CHOP chemoimmunotherapy for completely resected limited-stage diffuse large B cell lymphoma (CISL 12-09). Ann Hematol. 2020 Dec;99(12):2831-2836. doi: 10.1007/s00277-020-04284-z. Epub 2020 Sep 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cyclophosphamide	Other / unclassified	750 mg/m2	Intravenous
Subject	Doxorubicin	Other / unclassified	50 mg/m2	Intravenous
Subject	Prednisolone	Other / unclassified	100 mg	Oral
Subject	Rituximab	Monoclonal antibody	375 mg/m2	Intravenous
Subject	Vincristine	Small molecule	1.4 mg/m2	Intravenous

Abbreviated R-CHOP in Completely Excised Stage I or II DLBCL

Summary

Timeline

Publications

Drugs

Indications